OTCPicks.com

FEATURED COMPANY

BIOSOLAR INCORPORATED (OTC: BSRC)
"Up 5.56% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/BSRC.php

Company Profile: http://www.otcpicks.com/biosolar/biosolar-2.htm

BioSolar, Inc. engages in the research and development of bioplastic materials from renewable plant sources for use in photovoltaic solar cells. The company develops bio-based plastics components that meet the thermal and durability requirements of solar cell manufacturing processes for conventional crystalline cell designs, as well as thin film photovoltaic devices in an effort to capitalize on cost advantages to current petroleum based solar cell components. Its bioplastic materials can be also used directly in conventional manufacturing systems, such as injection molding and thin-film roll-to-roll, to create superstrate layer, substrate layer, and backsheet, as well as module and panel components. The company was founded in April 2006. It was formerly known as BioSolar Labs, Inc. and changed its name to BioSolar, Inc. in June 2006. BioSolar, Inc. is headquartered in Santa Clarita, California.

BSRC News:

June 11 - BioSolar Highlighted Nationally in Media Reports Focused on Growth of Solar Market and Company's Competitive Advantage

Company's BioBacksheet™ Causing Industry-Wide Interest in Shift to Petroleum-Free Components to Ensure that Entire Solar Industry Becomes Financially Sustainable

BioSolar™, Inc. (OTCBB: BSRC), developer of a breakthrough technology to produce bio-based materials from renewable plant sources that reduce the cost of photovoltaic solar cells, has been cited in recent news media reports exploring the increasing demand for bio-based solar cell components, which will help the entire industry make photovoltaic solar cells more financially viable by substantially lowering the cost of the cells through the use of petroleum-free materials.

In this week’s CLEANTECH column in energy trade publication California Energy Circuit, (CLEANTECH: Making Solar Power Fossil Free, June 6 2008 issue), energy correspondent William J. Kelly discusses the concept of life-cycle testing — utilizing the entire life-cycle of a product and its components to determine its total carbon footprint — noting that solar cells generate 0.04 kilograms of carbon dioxide per kilowatt of electricity generated.1 The article goes on to note that clean energy researchers see that level declining dramatically due to improvements in the materials used to make the solar cells.

“This article recognizes that BioSolar’s BioBacksheet™ is quickly becoming a driving force in a shift to replace plastic petroleum-based solar cell components with environmentally-friendlier fossil-free ones derived from plant-based products,” said Dr. David Lee, CEO of BioSolar. “This industry-wide trend is expected to continue accelerating as the cost benefits of bio-based products continue to far outperform petroleum-based products. Plus, by making solar cells fossil-free, we are also making the solar cell — and the entire solar industry — more financially sustainable. Products like the BioBacksheet™, among other new products from BioSolar, are helping the industry attain its long sought goal of weaning itself from governmental subsidies and achieving economic viability.”

BioSolar was also the subject of a piece in GreenTech Pastures, veteran newsman Harry Fuller’s column at ZDnet.com (http://blogs.zdnet.com/green/?p=1083). Noting that BioSolar’s “BioBacksheet” is made entirely of plant-based materials, Mr. Fuller’s article states that BioSolar has found a “way to really green solar: turning green plants into photovoltaics.”

The article also highlights another compelling business point: while other bio-based plastics are made from corn-starch or potato-starch derivatives, which are currently experiencing a surge in price, all of the plant-based materials used by BioSolar’s products are made from plants that are non-food based. This bodes well for the company’s pricing and market penetration strategy because BioSolar is more insulated from the negative effects of the recent run-up in food commodity pricing.

“This article is further evidence that we are succeeding in our mission to lead the industry both in terms of appealing to our customer base as well as industry influencers and that the products in our development pipeline are poised to experience the same rapid market acceptance in the multi-billion dollar photovoltaic market,” said Lee.

FEATURED COMPANY

LANTIS LASER INCORPORATED (OTC: LLSR)
"Up 4.35% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/LLSR.php

Company Profile: http://www.otcpicks.com/lantis-laser/lantis-laser-2.htm

Lantis Laser was formed to commercialize the application of novel technologies in the dental industry. The criteria for selected products include competitive edge, exclusivity and large market potential. Lantis is currently in Phase 2 development, moving through beta systems, product development and application for FDA clearance and plans to launch the OCT Dental Imaging System™ in the first quarter of 2009. Lantis has exclusive rights to the application of OCT technology in the field of dentistry under its license Agreements with Lawrence Livermore National Laboratory (exclusive); LightLab Imaging (non-exclusive) and AXSUN (exclusive). To find out more about Lantis Laser, visit www.lantislaser.com.

LLSR News:

June 10 - Lantis Laser Commences Phase 3 Development of it's OCT Light-Based Dental Imaging System

Eclipse Product Development Selected for Design, Interface and Documentation Phase

Lantis Laser Inc. (OTC: LLSR) (www.lantislaser.com) announced that it has commenced Phase 3 of the development cycle of its proprietary, highly advanced Optical Coherence Tomography (OCT) Dental Imaging System™. The OCT System is a diagnostic light-based, chairside, system that images in real-time at a resolution of to 10 times x-ray and without any harmful radiation. It is expected to have a major impact on early diagnostics and the advancement of minimally invasive treatment once it is deployed in dental offices.

“Phase 3 development embodies a number of significant events in the evolution of OCT for dentistry,” said Stan Baron, president and CEO of Lantis. “The components of the OCT System that needed to be upgraded to meet the requirements of the fast scanning speed enabled by AXSUN Technologies swept source laser, are being readied for integration into the OCT Beta Systems. We expect to deploy the Beta Systems for clinical use in the July/August timeframe.”

Phase 3 of the product development cycle also requires that the OCT System’s mobile cart will be designed, that the user interface be refined and that documentation in preparation for the FDA filing be prepared. After an extensive review of product design companies, Lantis is pleased to announce that it has selected Eclipse Product Development to undertake this demanding task.

Vice President of Research and Development at Lantis, Doug Hamilton, commented, “OCT is not a modality that many companies have had experience with, so we looked for a company that had a solid industrial design core and the network to bring in the best available resources for each discipline that is deployed in the OCT System. Eclipse provides us with this development model and the flexibility we need to complete this Phase in an efficient and timely manner.”

“All the components leading to up to FDA submission, manufacturing and marketing are now being put into place,” said Baron. “We will be making regular announcements as we progress to keep the investment and dental community abreast of developments”.

ABOUT ECLIPSE PRODUCT DEVELOPMENT

Eclipse, located in Amesbury, MA has over 13 years of experience helping clients commercialize medical, laboratory and dental category technologies. The company is medically oriented and has designed numerous products including complex diagnostic and therapeutic medical and dental equipment and devices. Their development process meets FDA and ISO requirements for design control documentation and verification. Eclipse has developed a strategic business model to include several experienced molding and manufacturing vendor relationships.

FEATURED COMPANY

MONOGRAM ENERGY INCORPORATED (OTC: MGRN)
"Up 60.00% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/MGRN.php

Company Profile:
http://www.otcpicks.com/monogram-energy/monogram-energy.htm

Monogram Energy, Inc. is an independent energy company engaged in the acquisition, development, and exploitation of oil and gas properties. The company specializes in acquiring oil & gas leases with proven reserves that have the potential for increased production.

MGRN News:

June 2 - Monogram Energy, Inc. Announces 50% Production Capability Increase in Corsicana, Texas

Monogram Energy, Inc. (OTC: MGRN), an independent energy company engaged in the acquisition, development, and exploitation of oil and gas properties, announced that the Company's six wells on the T.W. Martin lease are currently producing, and that the three additional wells in the workover process should be completed by the end of June.

The 9 total wells are then expected to produce 2 barrels per day each for a projected yield of 540 barrels per month. This workover progress represents a 50% increase from the May 13th release projections of 270 barrels per month based on production estimates on the initial 6 wells.

The T.W. Martin lease comprises 70 acres with 12 wells and is located in Navarro County, Texas, which produces around 600,000 barrels annually.

"We're very pleased with our progress so far. With a little luck we might even complete our current workovers ahead of schedule," stated Mr. Billy King, Chief Executive Officer of Monogram Energy, Inc.

Mr. King became interested in the production of oil & gas during his ten years of employment as an attorney for the Halliburton Company, and with his representation of independent oil companies during his years as a private practitioner. Monogram Energy's goal is to maintain a high risk/reward profile, thereby enabling them to return the most value to its shareholders.

FEATURED COMPANY

GENERAL AUTOMOTIVE COMPANY (OTCBB: GNAU)

Detailed Quote: http://www.otcpicks.com/quotes/GNAU.php

Company Profile:
http://www.otcpicks.com/general-automotive/general-automotive-2.htm

General Automotive Company ("GAC") is a provider of original equipment and aftermarket automotive parts, mobile electronics, and related automotive products at multiple levels of distribution throughout the United States and internationally. Through its two wholly owned subsidiaries, Global Parts Direct and OE Source, the company focuses its efforts on utilizing its relationships with manufacturers in China, Korea and Japan to bring state-of-the-art automotive parts, accessories and products to automobile manufacturers and major parts distributors in the U.S. For more information on GAC and its products, visit www.generalautomotive.com.

GNAU News:

June 10 - General Automotive Expands Board of Directors

Managing Partner of Charter Oak International and Former Top Saab Executive Join Board

General Automotive Company (OTCBB: GNAU), a provider of original equipment and aftermarket automotive parts, mobile electronics and related products, announced that Anthony J. Dowd and Kenneth F. Adams have joined its Board of Directors.

Anthony Dowd is the Managing Partner of the private equity partnership, Charter Oak International Partners, as well as a General Partner of Charter Oak Partners, a 32-year-old equity hedge fund. During his 16 years at Charter Oak, Dowd has directed and led the partnerships’ acquisition of, or investment in, privately held businesses. Since founding Charter Oak’s private equity business, Dowd and his team have completed more than 45 acquisitions.

Kenneth Adams, who will serve as Chairman of GA’s Audit Committee, was Vice President and Chief Financial Officer of Saab Cars USA, Inc., a subsidiary of General Motors Corporation and a wholesale distributor of Saab cars, parts and accessories with annual sales of more than $1 billion, for 13 years. He also served on the company’s Board of Directors from 1992 until his retirement in 2005. Adams joined Saab in 1974 as Treasurer and held roles of increasing responsibility over his 31 years with the company. In addition to being responsible for all its financial activities, controls and reporting as CFO, he was a member of the executive team, operations team and chairman of the pension committee.

“Tony and Ken’s vast experience in corporate finance and their business insights will be extremely valuable to General Automotive as we pursue our strategy of growth by acquisition,” commented President and CEO Joseph DeFrancisci. “It is an honor to have people of their stature join our team and help us further GA’s growth and success as we expand our portfolio of operating companies.”

Prior to joining Charter Oak Partners, Dowd was a Senior Associate with James D. Wolfensohn, Inc., a New York-based investment banking firm that advised large domestic and international corporations on mergers and acquisitions. He graduated with distinction from the U.S. Military Academy at West Point with a B.S. Degree in Engineering and earned an M.B.A. from the Wharton School of the University of Pennsylvania. Dowd currently serves on the Board of Directors of several privately held businesses.

Prior to joining Saab in 1974, Adams was an audit manager with Price Waterhouse for six years. A CPA, he received a BS in Finance from Mount Saint Mary’s University. He previously served as a Director and Chairman of the Audit Committee for Telzuit Medical Technologies, Inc.

The election of Dowd and Adams brings the total number of General Automotive directors to five.

FEATURED COMPANY

CARBON SCIENCES INCORPORATED (OTCBB: CABN)

Detailed Quote: http://www.otcpicks.com/quotes/CABN.php

Company Profile:
http://www.otcpicks.com/carbon-sciences/carbon-sciences-2.htm

Carbon Sciences, Inc. focuses on developing GreenCarbon technology to convert carbon dioxide into a form that would not contribute to global warming. Its GreenCarbon technology is targeted at coal-fired electrical power plants and fuel production plants. The company was founded in 2006 as Zingerang, Inc. and changed its name to Carbon Sciences, Inc. in April 2007. Carbon Sciences, Inc. is based in Santa Barbara, California.

CABN News:

June 10 - Changing Political Climate May Create Massive Market Opportunity for Carbon Sciences

Carbon Sciences, Inc. (OTCBB: CABN), the developer of a breakthrough technology to transform harmful carbon dioxide (CO2) into high value, earth-friendly products, announced its support of regulations to curb emissions of carbon dioxide.

"The political winds have recently shifted in a direction that appears to be very favorable for companies, such as ours, that offer carbon mitigation solutions," stated Derek McLeish, CEO of Carbon Sciences. "Senators John McCain and Barack Obama, the presumptive presidential nominees of their respective political parties both favor regulation. On the Congressional level, the climate change bill sponsored by Senators Joe Lieberman, John Warner and Barbara Boxer has been praised as one of the most important pieces of legislation in a long time. We heartily endorse their efforts."

Last week, Senator McCain launched his November election campaign by vowing to free America from dependence on foreign oil and cited his plans to cut emissions and fight global warming — a clear break from the current administration's energy policy. Democratic nominee, Senator Obama, also announced his support of plans to cap U.S. greenhouse gas emissions.

Active deliberation of legislation is favorable for Carbon Sciences. While the company's current business strategy does not depend on governmental legislation for initial commercial success, the passing of any form of legislation that would regulate carbon dioxide emissions could instantly open up a massive market for the company's breakthrough carbon transformation technology.

Mr. McLeish commented further, "We are in full support of these legislative efforts. Perhaps a successful bill may take a different shape than the current Senate proposal, but we believe that serious political action is highly likely to occur no later than early next year."

"We live in a very exciting time," continued Mr. McLeish. "Since announcing our clean-tech PCC strategy last month, we have received numerous inquiries from interested business partners. The outlook is very encouraging. There aren't many entrepreneurial opportunities in a person's lifetime where one can create great value while serving a noble cause. John Doerr, the legendary Silicon Valley venture capitalist, stated it well when he said that stopping global warming is the largest economic opportunity of the 21st century, and a moral imperative. We agree and are very excited to help meet this challenge."

STOCKS TO WATCH

ACCENTIA BIOPHARMACEUTICALS (NASD: ABPI)
"Up 33.94% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/BPAX.php

Accentia Biopharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, develops and commercializes drug candidates that are in late-stage clinical development based on active pharmaceutical ingredients in the therapeutic areas of respiratory disease and oncology. It operates in two segments: Biopharmaceutical Products and Services, and Specialty Pharmaceuticals. The Biopharmaceutical Products and Services segment develops late-stage biopharmaceutical products. Its products, which are under Phase III clinical trials, include SinuNase for the treatment of chronic rhinosinusitis; BiovaxID, a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkins lymphoma; and Revimmune for the treatment of multiple sclerosis, an autoimmune disease that affects the central nervous system, and various autoimmune diseases, including systemic lupus, myasthenia gravis, and aplastic anemia. This segment also provides various consulting services relating to biopharmaceutical product development; and engages in the production of custom biologic products and cell culture instruments and systems for biopharmaceutical and biotechnology companies, medical schools, universities, hospitals, and research institutions. The Specialty Pharmaceuticals segment markets and sells pharmaceutical products that are developed primarily by third-party development partners. Its products comprise Respi-TANN, a prescription antitussive decongestant for temporary relief of cough and nasal congestion; SinuTest, a test used in connection with the diagnosis of chronic sinusitis; and Zinotic, a treatment of superficial infections of the external ear. This segment's products under development include AllerNase, a formulated suspension of an intranasal topical steroid indicated for the treatment of allergic and non-allergic rhinitis; and Emezine, a product for control of nausea and vomiting. The company was founded in 2002 and is headquartered in Tampa, Florida.

ABPI News:

June 11 - Biovest Reports Blinded Results for Phase 3 Study Evaluating Anti-Cancer Vaccine, BiovaxID(R), which Shows 100% Difference in Disease-Free Survival at 36 Months in the Comparative Arms

Final Unblinded Results Are Expected to Confirm Efficacy Of BiovaxID for the Treatment of Non-Hodgkin's Lymphoma

Biovest International, Inc. (OTCBB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASD: ABPI), reported what the Company believes to be highly encouraging blinded results from its randomized controlled pivotal Phase 3 Fast-Tracked clinical trial of BiovaxID® (anti-idiotype vaccine) for the treatment of indolent follicular non-Hodgkin’s lymphoma (NHL), an often fatal blood cancer.

The Company reported blinded disease-free survival data for those patients that have completed 36 months of follow-up subsequent to randomization in both the treatment and control arms, with one arm demonstrating 100% improvement in disease-free survival over the other arm. Disease-free survival (how long patients remain in cancer-free remission) is the primary endpoint of the study.

According to Steven Arikian, M.D., Chairman and CEO of Biovest International, “In the accompanying graph, one curve shows those patients at 36 months in the BiovaxID arm and the other curve shows those patients at 36 months in the control arm who received a non-specific immunostimulant (KLH/GM-CSF).

“Although these results are blinded, this data shows two distinct populations in the study, with unequivocal evidence of a difference in disease-free survival among the two arms. This is in direct contrast to previous anti-NHL vaccine failures which showed little difference between the treatment arm and the control arm. Based on the similar pattern to our Phase 2 data, we have a high degree of confidence that the cohort demonstrating superior disease-free survival represents the BiovaxID arm,” stated Dr. Arikian.

Dr. Angelos Stergiou, Biovest’s Vice President, Product Development, added, “We know that in our Phase 2 trial, the control arm showed a median disease-free survival of approximately 20 months, which is consistent with the inferior arm in our blinded Phase 3 results, and supports our strong belief that the group demonstrating clinical benefit is the BiovaxID arm.”

ABOUT BIOVAXID®

BiovaxID is a personalized, patient-specific therapeutic vaccine designed to stimulate the patient's own immune system to recognize and destroy cancerous B-cells that may remain in the body or may arise after the patient has been treated with chemotherapy. Unlike many other approaches to treating non-Hodgkin’s lymphoma, BiovaxID is designed to kill only cancerous B-cells, with the initial indication of follicular non-Hodgkin's lymphoma. Additionally, we anticipate that BiovaxID could potentially be used to treat other types of B-cell cancers, such as Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma.

ABOUT BIOVEST INTERNATIONAL INC.

Biovest International, Inc. is a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. Biovest is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., with its remaining shares publicly traded. Biovest has a foundation in the manufacture of biologics for research and clinical trials. In addition, Biovest develops, manufactures and markets patented cell culture systems, including the innovative AutovaxID™, which is being marketed as an automated vaccine manufacturing instrument and for production of cell-based materials and therapeutics. Biovest is currently conducting a pivotal Phase 3 clinical trial for BiovaxID®, which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID has been granted Fast Track status by the FDA and Orphan Drug status by the EMEA.

BIOVEST INTERNATIONAL INCORPORATED (OTCBB: BVTI)
"Up 24.39% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/BVTI.php

Biovest International, Inc., a biotechnology company, develops therapeutic anti-cancer vaccine for the treatment of low-grade Follicular Lymphoma in the United States. It develops BiovaxID, a Phase III clinical trial product, which is an injectable patient-specific vaccine to treat the follicular form of non-Hodgkin's lymphoma. The company develops, manufactures, and markets cell culture systems, equipment, and consumable parts to pharmaceutical, diagnostic, and biotechnology companies, as well as to research institutions worldwide. Biovest International also produces mammalian and insect cells, monoclonal antibodies, recombinant and secreted proteins, and other cell culture products using hollow fiber perfusion. It is also developing an automated cell culture instrument, AutovaxID that enables production of personalized cell-based treatments. In addition, the company sells hollow fiber bioreactors, cultureware, tubing sets, and other disposable products and supplies. Further, Biovest International engages in the production and contract manufacture of biologic drugs and cell production for research institutions. The company has a cooperative research and development agreement with the National Cancer Institute for the development and commercialization of patient-specific vaccines for the treatment of non-Hodgkin's low-grade follicular lymphoma. Its customers include biopharmaceutical and biotech companies, medical schools, universities, research facilities, hospitals, and public and private laboratories. The company was incorporated in 1981 as Endotronics, Inc. and changed its name to Cellex Biosciences, Inc. in 1993. Further, it changed its name to Biovest International, Inc. in 2001. The company is based in Worcester, Massachusetts. Biovest International, Inc. is a subsidiary of Accentia Biopharmaceuticals, Inc.

BVTI News:

June 11 - Biovest Reports Blinded Results for Phase 3 Study Evaluating Anti-Cancer Vaccine, BiovaxID(R), which Shows 100% Difference in Disease-Free Survival at 36 Months in the Comparative Arms

Final Unblinded Results Are Expected to Confirm Efficacy Of BiovaxID for the Treatment of Non-Hodgkin's Lymphoma

Biovest International, Inc. (OTCBB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASD: ABPI), reported what the Company believes to be highly encouraging blinded results from its randomized controlled pivotal Phase 3 Fast-Tracked clinical trial of BiovaxID® (anti-idiotype vaccine) for the treatment of indolent follicular non-Hodgkin’s lymphoma (NHL), an often fatal blood cancer.

The Company reported blinded disease-free survival data for those patients that have completed 36 months of follow-up subsequent to randomization in both the treatment and control arms, with one arm demonstrating 100% improvement in disease-free survival over the other arm. Disease-free survival (how long patients remain in cancer-free remission) is the primary endpoint of the study.

According to Steven Arikian, M.D., Chairman and CEO of Biovest International, “In the accompanying graph, one curve shows those patients at 36 months in the BiovaxID arm and the other curve shows those patients at 36 months in the control arm who received a non-specific immunostimulant (KLH/GM-CSF).

“Although these results are blinded, this data shows two distinct populations in the study, with unequivocal evidence of a difference in disease-free survival among the two arms. This is in direct contrast to previous anti-NHL vaccine failures which showed little difference between the treatment arm and the control arm. Based on the similar pattern to our Phase 2 data, we have a high degree of confidence that the cohort demonstrating superior disease-free survival represents the BiovaxID arm,” stated Dr. Arikian.

Dr. Angelos Stergiou, Biovest’s Vice President, Product Development, added, “We know that in our Phase 2 trial, the control arm showed a median disease-free survival of approximately 20 months, which is consistent with the inferior arm in our blinded Phase 3 results, and supports our strong belief that the group demonstrating clinical benefit is the BiovaxID arm.”

ABOUT BIOVAXID®

BiovaxID is a personalized, patient-specific therapeutic vaccine designed to stimulate the patient's own immune system to recognize and destroy cancerous B-cells that may remain in the body or may arise after the patient has been treated with chemotherapy. Unlike many other approaches to treating non-Hodgkin’s lymphoma, BiovaxID is designed to kill only cancerous B-cells, with the initial indication of follicular non-Hodgkin's lymphoma. Additionally, we anticipate that BiovaxID could potentially be used to treat other types of B-cell cancers, such as Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma.

ENZYME ENVIRONMENTAL SOLUTIONS (OTC: EESO)
"Up 12.50% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/EESO.php

Enzyme Environmental Solutions is a U.S.-based manufacturer of industrial and agricultural enzyme products. All manufacturing, testing, and formulating are conducted in its manufacturing plant, located in Fort Wayne, Indiana. EESO strives to become a leader in ecological friendly or “green products” targeting the industrial and agricultural markets. It is the company's goal to have the best performing products on the market in each industry. Developing a growing and satisfied customer base is its number one marketing strategy.

EESO News:

June 11 - Enzyme Environmental Solutions Finalizes Agreement With Canada's Largest Food Service Brokerage

Enzyme Environmental Solutions Inc. (OTC: EESO) CEO S. Jared Hochstedler announced that the company has finalized the agreement to supply International Pacific Sales, LTD with sustainable cleaning products.

Hochstedler commented, "I am extremely pleased to announce that EESO has now contracted with International Pacific Sales, LTD, www.internationalpacificsales.com, to supply our enzyme based cleaning products across all of western Canada."

Hochstedler continued, "This is another huge step for the company. I have been negotiating with International Pacific Sales, LTD for several weeks and am proud to be associated with such a prestigious company. International Pacific Sales, LTD is well known for its integrity, stability and high standards of professionalism. Mike Discroll, President of IPS, was the first Food Service broker to receive the 'We Care Hall of Fame Award.'"

The Company projects revenues between $2 and $4 million over the next 12 months with initial revenues beginning in July and in full swing by the end of the third quarter 2008.

"This continues to be an exciting time for our company. I am getting calls from in and outside the U.S. inquiring about our products. There has been much effort from everyone absorbing the efforts of our sales team that took place in the preceding months. The build out of the office and warehouse is just about completed and we have scheduled our Grand Opening for June 27, 2008. However all shareholders should feel free to stop in anytime," stated Hochstedler.

"I will be providing some updated revenue projections for 2008 and 2009 in the coming days; however I am pleased with the progress we have made thus far. On line sales have continued to outpace my expectations and I am pleased to relay we have received very positive feedback concerning the effectiveness of our products," concluded Hochstedler.

CYBERHAND TECHNOLOGIES INTERNATIONAL (OTC: CYHA)
"Up 18.42% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/CYHA.php

CyberHand Technologies International, Inc., through its Canadian operating subsidiary, design, market, sell, distribute and provide service for new consumer electronic technologies. These products use innovative ergonomic designs and technologies that are superior to other products in the market. The initial product offering includes: Computer Game Controllers that are 40% more responsive then the competitor's products; Wireless Keyboards for Personal Digital Assistants (PDAs"); Ergonomic Computer Mouse Product line that eliminates computer related Respective Stress Injuries; and Related Software Upgrades and other peripherals such as Keyboards, Cameras and Scanners. The products are patent protected in both Canada and the United States.

CYHA News:

June 10 - Black Widow Prerelease for Gamers Who Want an Edge

Cyberhand Technologies International Inc. (OTC: CYHA), a design, marketing and distribution company providing new consumer electronic technologies using innovative ergonomic designs, today announced its subsidiary, Cyberhand Robotics, has moved to the field testing of its first controller on the gaming and engineering design marketplace. The first product is called the "Black Widow" and will be accompanied by a Pro version almost immediately for more serious gamers. It is far faster than any gaming controller offered at any price, cannot cause any of the five carpel tunnels of any of the RMS problems normally associated with fast accurate use of pointing devices and allows substantially longer game play without fatigue. This is the first in a line of patented advanced controllers that will be offered by the company.

"Cyberhand will be releasing 500 of its Black Widow controllers to qualified testers who will receive a fifty percent (50%) discount to release retail for their participation and control testing in advance of its fall release. They must sign a strict non-disclosure agreement and provide the company feedback and suggestions. All interested testers will be able to sign up on the company website. The Controller allows you to fight harder, move faster, dodge at lightning speed, play for hours without fatigue or pain and crush your opponents. You will be able to design faster, connect pieces easier and relax while you do complex on-screen tasks like you have never experienced them before. At Cyberhand, we invite you to come and test the Black Widow and help change the world of gaming pointing devices forever!" said Patrick Burke, Inventor at Cyberhand Technologies International Inc.

ABOUT CYBERHAND ROBOTICS

Cyberhand Robotics Corporation, a subsidiary of Cyberhand Technologies International Inc., is a new Company that consists of all the technology and intellectual property related to the development of an Ergonomic Computer Mouse and a line of Computer Game Controllers. A unique feature of the Ergonomic Computer Mouse is its ability to eliminate computer related respective stress injuries such as carpal tunnel syndrome. The Computer Game Controllers integrate hand movement which, in turn, permit a variety of control functions to be performed by a single left or right handed operation resulting in a significant increase in response times over competing products making it the fastest, most intelligent, and most comfortable first person shooter controller on the market. In the gaming world, where split second timing and agility determine the winners and losers, the Company's game controllers place users at the top of any game as they are 40% more responsive than competitor products. The markets for the Company's products are huge, consisting of the Computer Peripheral market with over 600,000,000 users worldwide and the Computer Gaming Peripherals market estimated at $6 billion dollars in the U.S. alone, with this market growing at the rate of 34% per year.

CELSIUS HOLDINGS INCORPORATED (OTCBB: CSUH)
"Up 51.26% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/CSUH.php

Celsius Holdings, Inc., through its subsidiaries, Celsius Inc. and Celsius Netshipments, Inc., engages in the production, distribution, and marketing of functional beverages in the United States. The company offers CelsiusR, a calorie burning soda, which is available in cola, ginger ale, lemon/lime, orange, and wild berry flavors. It also sells its products through the Internet. The company was founded in 2004 and is based in Delray Beach, Florida.

CSUH News:

June 10 - 4th Clinical Study on Celsius Shows Additional Benefits with Exercise

Celsius Enhances 10-Week Exercise Program; Delivering More Loss of Fat Mass and More Gain of Muscle Mass

Celsius Holdings, Inc. (OTCBB: CSUH) reported the preliminary results of yet another completed phase of scientific research, conducted at the Metabolic and Body Composition Laboratory of the Department of Health and Exercise Science, at the University of Oklahoma (Norman, OK). At a meeting of the International Society of Sports Nutrition held in Las Vegas, Nevada, a fourth clinical study of Celsius, the original calorie burning beverage, was unveiled showing that consumption of Celsius® as a pre-workout beverage resulted in dramatic improvements in the benefits of exercise among a test group of previously sedentary individuals.

The first phase of the study showed that drinking a single 12oz. serving of Celsius per day for 10 weeks dramatically improves the benefits of light to moderate exercise. The test subjects consuming Celsius lost significantly more fat mass and gained more muscle mass than subjects drinking the placebo, and significantly improved their cardiovascular endurance during exercise.

According to the preliminary findings of the study, those subjects consuming a single serving of Celsius lost significantly more fat mass and gained significantly more fat-free mass (muscle mass) than those subjects consuming the placebo – a 93.8% greater loss in fat and 50% greater gain in fat-free mass, respectively. The study also confirmed that subjects consuming Celsius significantly improved measures of cardio-respiratory fitness (VO2peak) and the ability to delay the onset of fatigue when exercising to exhaustion (time-to-exhaustion). In fact, the Celsius group outperformed those consuming the placebo by 62.5% for VO2peak and 32.5% for time-to-exhaustion.

Celsius Holdings, Inc. has previously reported on breakthrough findings on other clinical studies dating back to June 11, 2005, when its first clinical study was presented at a meeting of the International Society of Sports Nutrition in New Orleans. In addition to showing that a single 12oz. serving of Celsius burns up to 100 calories, additional studies have shown that the impact of Celsius does not attenuate and that test subjects showed the calorie burning benefits of Celsius over a 28-day period, with no clinically adverse changes to important health markers.

This most recent 10-week blinded placebo-controlled study was conducted on a total of 37 previously sedentary men and women. Subjects were randomly assigned into one of two groups: Group 1 consumed one serving of Celsius per day, and Group 2 consumed one serving of an identically flavored and labeled placebo beverage. Both groups participated in 10 weeks of combined aerobic and weight training, following the American College of Sports Medicine guidelines for previously sedentary adults. Fifteen minutes prior to each workout, participants consumed Celsius or the placebo; on non-training days, subjects consumed one beverage at any time of their choosing. Subjects’ diet was left uncontrolled (i.e. subjects were not instructed to change their diet).

“This study suggests that Celsius provides a significant, additive adaptation to the benefits of regular exercise,” stated Jeffrey R. Stout, Ph.D., who served as the Chief Researcher on the study, at the University of Oklahoma. “Specifically, consuming Celsius prior to exercise appears to augment ones’ training response to both aerobic and resistance (weight) training. Furthermore,” said Stout, “because we didn’t observe a statistically significant difference in strength between groups, but instead found significant improvements in body composition and cardiorespiratory fitness in those consuming the Celsius beverage, there appears to be preferential sequestering of fat for fuel, occurring both during exercise and while at rest. The same findings were previously reported out of Dr. Kerkisk’s lab.” Dr. Stout concluded by stating, “these are very interesting findings that, in my opinion, will set the tone for how people maximize their workouts. – Now it can be scientifically supported that, by consuming a pre-workout calorie burning beverage, a person can improve their response to exercise; however, these claims are unique to Celsius.”

“This latest clinical study, the fourth one with Celsius, exemplifies our commitment to solid clinical research. It clearly extends the proven functionality of Celsius to improving the benefits of regular exercise. This study confirms what the scientists have always told us, but the results are significantly better than what we anticipated,” said Steve Haley, CEO of Celsius, Inc. “This most recent study, where we combined Celsius and exercise, was the next logical step in clinical research and further demonstrates our commitment to providing healthier choices so people can easily make lifestyle changes, live healthier lives and attain their fitness goals.”

ABOUT CELSIUS®

Celsius, the original, great tasting calorie burner, is a healthier choice that has been clinically shown to burn calories by raising metabolism and significantly enhances the benefits of regular exercise. The most recent clinical studies show significant increases in the benefits of exercise when consuming a single serving of Celsius before physical activity. Celsius contains Metaboost™, a proprietary blend of ingredients including Green Tea with EGCG, Ginger, Calcium, Chromium, B Vitamins, and Vitamin C.

MAMMOTH ENERGY GROUP (OTC: MMTE)
"Up 22.22% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/MMTE.php

Golden Eagle International, Inc. mines and explores for gold and copper minerals in the Republic of Bolivia. It holds interests in the Cangalli and Tipuani Valley gold properties covering 12,000 acres in western Bolivia; and the Precambrian properties covering 136,500 acres in eastern Bolivia. The company, formerly known as Beneficial Capital Financial Services Corp., was founded in 1988 and is headquartered in Salt Lake City, Utah.

MMTE News:

June 11 - Mammoth Energy Group, Inc. Announces That Drilling Will Take Place in Similar Area as Other Oil Companies

Mammoth Energy Group, Inc. (OTC: MMTE) announces that it will begin drilling in the same area as AGGI and NFX. AGGI, another oil and gas company, had record sales and growth in 2007 with net revenues of $709,894.00 and gross revenues of over $9,000,000.00. Mammoth Energy currently holds 1,400 acres in the same area, as it is looking to exploit the geological values of this area. Mammoth Energy can really benefit from drilling in an area that is rich in oil and gas.

"This area of operation is very hot for oil and energy companies," stated CEO and President Joe Overcash. "This will give Mammoth a chance to get a piece of the action in this area."

CANADIAN ZINC CORPORATION (OTCBB: CZICF)
"Up 15.15% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/CZICF.php

Canadian Zinc Corporation is a Toronto listed junior exploration company, trading under the symbol CZN. The company’s main project is the Prairie Creek Silver & Zinc mine in Canada. The Company has an experienced executive team and board based in Vancouver BC. Canadian Zinc’s long-term aim is to bring the 100%-owned Prairie Creek Mine in the Mackenzie Mountains of the Northwest Territories into production at the earliest possible date. The mine, which has a fascinating history, is a silver and base metals property already in the advanced stages of development, with substantial resources of high-grade silver, zinc, and lead. Exposures of mineralized vein structures, which overly thicker Stratabound mineralization, both of which are included in the present resource, are known to occur over a distance of 16 KM's through the property.

CZICF News:

June 10 - Canadian Zinc Submits Permit Applications for Production at the Prairie Creek Mine

Canadian Zinc Corporation (OTCBB: CZICF) (Toronto: CZN) (the "Company" or "Canadian Zinc") is extremely pleased to announce that applications have been submitted to the Mackenzie Valley Land and Water Board (the "MVLWB") for permits for the proposed operations and production at the Prairie Creek Mine (the "Project") in the Northwest Territories.

After completing numerous exploration, engineering, environmental studies, and recently completing a major underground development and metallurgical program, CZN has now applied for a Type "A" Water Licence and Type "A" Land Use Permit ("LUP") for the operation of the Prairie Creek Mine.

The proposed new operation at Prairie Creek utilizes the extensive existing infrastructure and facilities that were built in the 1980's which will be upgraded and enhanced to meet the highest environmental standards. The improvements proposed for specific site facilities will further mitigate the potential impact the Project may have on the environment. For example, the permanent disposal of filtered mill tailings as underground backfill instead of on the surface is proposed.

"It has taken a long time to get to this point but the location of the Project has always dictated a very stringent approach to environmental management and mitigation" said Chief Operating Officer Alan Taylor. Since 2001 various aspects of the project have already been subjected to five environmental assessments by the Mackenzie Valley Environmental Impact Review Board and Canadian Zinc has successfully obtained five land use permits and a Type "B" water licence to carry out the necessary exploration and development programs at the mine site. The Company currently holds a Type "B" Water Licence and Land Use Permit for underground exploration and development and metallurgical testing and a Land Use Permit for surface exploration throughout the Prairie Creek property. The Company also holds a Land Use Permit and a Water Licence for the use and repair of the existing road that connects the mine with the Liard highway.

"As a result of its previous experience in obtaining permits the Company has first-hand knowledge of the Mackenzie Valley permitting process and has incorporated extensive responsible environmental mitigative measures within this application. In turn, the regulatory and government agencies have developed a good understanding of the Prairie Creek Project, all of which should assist in expediting the new permit applications." Alan Taylor added.

The permit applications are currently under review by the MVLWB at this time and may be viewed on the MVLWB website at www.mvlwb.ca or on the Company website at www.canadianzinc.com.

The Proposed Prairie Creek Mine Operation:

Mineral Resource Basis

The Prairie Creek Mine mineralization occurs as both Vein and Stratabound type deposits. Based on a recently completed detailed underground exploration and development program an updated mineral resource was calculated in 2007 (in accordance with the requirements of National Instrument 43-101 Standards for Disclosure for Mineral Projects) which defines an overall Measured and Indicated Mineral Resource totalling 5,158,164 tonnes grading 10.8% Pb, 11.3% Zn, 175 g/t Ag and 0.4% Cu. This is sufficient for more than 10 years of operations at the planned production rates. In addition, there is an open-ended inferred resource of 5,541,576 tonnes grading 11.4% Pb, 13.5% Zn, 215 g/t Ag and 0.5% Cu. Mineral resources were reported in a 43-101 compliant Technical Report dated October 12, 2007, prepared by MineFill Services Inc. (Dr. David Stone and Stephen Godden — Qualified Independent Persons).

Environment

Extensive environmental data has been collected at the Prairie Creek Mine Site over recent years to update and add to the baseline information that was collected previously as far back as the late 1970's. Sixteen years of water flow data have been recorded on the Prairie Creek watercourse adjacent to the Mine Site. CZN now has an extensive database on water quality, stream flows, local climatic variables, and the wildlife in the area.

The Mine

All mining will be performed from underground. Underground development and workings (about 5,000 metres) already exist on three levels, including the new 600 metre decline driven in 2006/07. Proposed production rates will initially start at 600 tonnes/day and will build to 1,200 tonnes/day. Mining will occur on a year round basis by cut-and-fill methods. Mine voids will be backfilled with a mix of filtered tailings, waste rock aggregate and cement. The current planned mine life is 14 years.

The Mill

The Mill, which is already constructed on site but never operated, will process 600-1,200 tonnes/day. Ore will be crushed to a gravel-size and subjected to dense media separation ("DMS"). The lighter, uneconomic "gangue" minerals (about 30%) will create a waste rock aggregate. Denser material will be processed further by grinding and flotation to produce concentrates of lead sulphide, zinc sulphide and lead oxide. No hazardous chemicals will be used in the process.

Concentrates and Road Haul

The concentrates will be bagged, stored under cover and trucked off-site on flat-deck trailers over the winter road. CZN holds a Type "A" LUP (MV2003F0028) for the use of the winter road from the Prairie Creek Mine to the Liard Highway. The permit for the existing road has been determined to be exempt from environmental assessment (Canadian Zinc Corporation vs. MVLWB, NWT Supreme Court, 2004). CZN has also applied for Type "A" LUP's for two new transfer facilities to be located approximately mid-point along the winter road and at the junction of the winter road with the Liard Highway.

Waste Management

All flotation tailings will be backfilled into the voids in the underground mine in a mix with the waste rock aggregate and cement. The flotation tailings are expected to be non-acid generating with low sulphide content and excess buffering capacity. Waste rock from underground development along with excess waste rock aggregate from the DMS plant will be placed in an engineered Waste Rock Pile ("WRP") in the adjacent Harrison Creek valley.

Water Management

An existing large pond, originally intended in 1980 for tailings disposal, will be reconfigured, relined and recertified to form a two-celled Water Storage Pond. Mine drainage, treated sewage water and WRP runoff will report to the first cell. Water for the mill process will be taken from this first cell. Excess water from the first cell will overflow into the second cell. Used water from the Mill will also report to the second cell. The second cell will feed a water treatment plant. The treated water will discharge to the existing certified Polishing Pond and from there into the existing Catchment Pond, before final discharge to the environment.

Site Infrastructure

The Site presently contains a near complete mill, three levels of underground workings, a fuel tank farm, office facilities, accommodation facilities and workshops. Existing buildings and structures will be upgraded and modernized. New facilities will include fuel-efficient low-emission power generation units, a kitchen/accommodation block, concentrate shed and an incinerator.

Socio-Economics and Manpower

The operation of the Prairie Creek Mine will provide substantial economic stimulus to the region, and presents a unique opportunity to enhance the social and economic well-being of the surrounding communities. There will be approximately 220 direct full time jobs, half of this number being on-site at any one time. Personnel will generally work a three weeks on, three weeks off schedule (with variations as required). CZN's objective is to employ a workforce with a 35% northern content, and a minimum 15% First Nations content assisted by training programs. In addition, there will be many indirect business and employment opportunities, mostly related to transport and supply of the Mine Site and environmental monitoring and management.

Mine Closure

At the end of the Mine's life, the Site will be reclaimed. The underground development will be backfilled. Bulkheads at strategic points will help limit the movement of groundwater. The objective is to create a complete seal to ensure there is no long term mine drainage. The WRP will be covered and sealed with a clay-rich soil. Site buildings and infrastructure, if deemed not to have any future use, will be dismantled and the Site will be returned to its natural setting.

Background

The Prairie Creek Mine ("Mine" or "Site") is 100% owned by Canadian Zinc Corporation ("CZN" or "Canadian Zinc"), and is situated in the southern Mackenzie Mountains of the Northwest Territories. The Site presently contains significant infrastructure and facilities constructed in the early 1980's. The Mine received a Water Licence (#N3L3-0932) and Land Use Permit (N80F248) in 1980 for mine operation and the production of lead and zinc concentrates and a silver-bearing copper concentrate. The Mine was within three months from production when the then owner was placed into receivership as a result of the decline in the price of silver.